Mezavant
In brief
- Mezavant can be obtained from community and hospital pharmacies; it is prescription-only in Australia and most countries—some online or international sellers may claim to supply it without a prescription, but buying prescription medicines without a valid prescription is not recommended for legal and safety reasons.
- Mezavant (mesalazine/mesalamine) is used to induce and maintain remission in mild-to-moderate ulcerative colitis, including proctitis and proctosigmoiditis; it works topically in the colon to reduce inflammation by modulating inflammatory mediators and inhibiting prostaglandin and leukotriene synthesis, with delayed/extended-release formulations releasing 5‑ASA in the colon.
- Usual adult dosing for active disease is 2.4–4.8 g/day orally in divided doses (for example 800 mg three times daily); maintenance dosing is typically 1.6–2.4 g/day; paediatric dosing where approved is approximately 50–75 mg/kg/day and 400 mg tablets are licensed from 5 years of age while 800 mg forms are often not approved for children.
- Administered orally as delayed- or extended-release tablets (commonly 400 mg or 800 mg) and, depending on brand, available in rectal forms such as enemas or suppositories for distal disease.
- Some patients notice symptomatic improvement within a few days to a couple of weeks, but onset is variable and meaningful improvement often takes days to weeks.
- Duration of action depends on continued daily dosing—Mezavant is used for induction (commonly 6–8 weeks) and for long‑term maintenance therapy, often continued for months to years as clinically indicated.
- There is no specific absolute alcohol prohibition, but avoid excessive alcohol as it can worsen gastrointestinal symptoms and general wellbeing; discuss alcohol use with your prescriber.
- The most common side effect is headache; other frequent effects include nausea, abdominal pain, diarrhoea or flatulence; rare but serious reactions include renal dysfunction and hypersensitivity reactions.
- Would you like to try “mezavant” without a prescription?
Critical Warnings & Restrictions (Safety First — Australian Context)
Basic Mezavant Information
- INN (International Nonproprietary Name): Mesalazine or Mesalamine (also known as 5‑aminosalicylic acid, 5‑ASA).
- Brand Names Available In Australia: Asacol, Asacol HD, Pentasa, Mezavant (Lialda in other markets), Salofalk, Rowasa and generic mesalazine products may be available depending on TGA listings and sponsor supply.
- ATC Code: A07EC02 — Drugs for treatment of inflammatory bowel disease; intestinal anti‑inflammatory agents; aminosalicylic acid and similar agents.
- Forms & Dosages: Delayed‑release tablets (400 mg and 800 mg examples such as Asacol/Asacol HD), rectal formulations (suppositories, enemas) depending on brand and local supply; packages commonly in 30/60/90 tablets.
- Manufacturers In Australia: Global manufacturers and distributors include Tillotts, Zeria, Allergan and Meda Pharma, with local generics supplied via licence agreements and TGA sponsors; specific Australian sponsors vary by product.
- Registration Status In Australia: Mesalazine products are prescription medicines; individual products must be checked on the TGA ARTG for registration and approved indications.
- OTC / Rx Classification: Prescription‑only (Rx) in Australia and other regulated markets due to the need for clinician supervision and monitoring.
High-Risk Groups (Elderly, Pregnancy, Chronic Illness)
- Older people with reduced renal function are at higher risk of renal adverse effects and need careful dosing and monitoring.
- Patients with chronic kidney disease or prior renal impairment carry increased risk and may require specialist review before starting mesalazine.
- People with known allergy to mesalazine, salicylates or sulfasalazine must not be given mesalazine.
- Pregnant or breastfeeding patients should only use mesalazine if the treating clinician judges the benefit outweighs the risk.
- Concurrent severe hepatic disease or recent liver injury requires caution and periodic liver tests while on therapy.
Monitoring Schedule
- Baseline serum creatinine and estimated glomerular filtration rate (eGFR) before starting mesalazine.
- Repeat renal function at 2–4 weeks after initiation or dose change, then every 3 months for the first year, and periodically thereafter as clinically indicated.
- Baseline liver function tests where liver disease is suspected, with periodic monitoring during treatment.
- Immediate renal testing for new symptoms such as reduced urine output, unexplained fatigue or peripheral oedema.
Pre-Prescription Screening Checklist
- Allergy history: mesalazine, aspirin, sulfasalazine, other salicylates.
- Recent renal function tests available and reviewed.
- Current medicines that may be nephrotoxic (NSAIDs, ACE inhibitors, aminoglycosides, diuretics).
- Pregnancy or breastfeeding status confirmed; discuss neonatal monitoring if used near delivery.
- History of severe liver disease or unexplained hepatic enzyme elevations.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Patients commonly ask whether mesalazine affects driving or heavy machinery operation.
Mesalazine rarely affects alertness but side effects such as dizziness or blurred vision can occur.
Anyone experiencing dizziness, visual disturbance or concentration problems should not drive or operate machinery until they have recovered.
Pharmacists should document counselling about fitness to drive in pharmacy records for medicolegal protection and workplace safety expectations such as Safe Work Australia guidance.
Q&A — “Can I Drive After Taking It In Australia?”
If you feel well with no dizziness, blurred vision or other side effects, driving is generally safe.
Stop driving and avoid operating heavy machinery if you develop symptoms that affect concentration, coordination or vision.
Seek medical advice promptly if such symptoms appear.
Report new or worrying symptoms to your prescriber or pharmacist immediately so fitness to drive can be reassessed.
Usage Basics
INN, Brand Names Available In Australia
Mesalazine is the INN for 5‑aminosalicylic acid (5‑ASA).
Common international brands include Asacol (delayed‑release tablets, 400 mg and 800 mg), Asacol HD (800 mg), Pentasa, Mezavant (Lialda in some markets) and Salofalk, with rectal formulations available depending on local supply.
Which specific brands are supplied in Australia depends on the sponsor and TGA ARTG listings.
Legal Classification (TGA‑Approved, PBS‑Listed)
Mesalazine products are prescription‑only medicines across jurisdictions.
TGA approval and ARTG entry are product specific; pharmacists should confirm the ARTG entry for the exact product supplied.
Some mesalazine formulations may be subsidised on the PBS for authorised indications and pack sizes; PBS status varies by product and indication.
- What to check on ARTG/PBS:
- ARTG number and approved indications for the exact brand and strength.
- PBS listing and authority requirements if subsidy is being claimed.
- Whether the product strength and pack size match PBS criteria for repeats and authority scripts.
Dosing Guide
Standard Regimens (PBS Reference Dosing)
Induction dosing in mild–moderate ulcerative colitis is commonly 2.4–4.8 g per day taken orally in divided doses.
For example, 800 mg three times daily is a commonly used induction schedule in adults.
Maintenance dosing is generally 1.6–2.4 g per day taken in divided doses.
Asacol 400 mg is approved for some paediatric patients aged five years and older where indicated; 800 mg formulations are typically for adults.
Induction courses commonly last six to eight weeks, with maintenance continued long term and reviewed periodically.
Adjustments For Comorbidities
Elderly patients should start at the lowest effective dose and have renal function checked frequently.
Mesalazine is contraindicated in severe renal impairment and should be avoided or used only after nephrology/medical advice in significant renal disease.
Use with caution in liver impairment and monitor liver enzymes as clinically indicated.
| Indication | Typical Adult Dose | Pediatric Notes |
|---|---|---|
| Mild–Moderate Active Ulcerative Colitis | 2.4–4.8 g/day orally in divided doses (eg, 800 mg three times daily) | 50–75 mg/kg/day divided; 400 mg formulations may be used ≥5 years |
| Maintenance Of Remission | 1.6–2.4 g/day orally in divided doses | Use paediatric dosing guidance and approved formulations |
| Topical Proctitis/Proctosigmoiditis | Rectal formulations as prescribed | Formulation dependent; follow product leaflet |
Baseline Tests Checklist
- Serum creatinine and eGFR before starting therapy.
- Liver function tests if hepatic disease suspected.
- Allergy screening for salicylates/sulfasalazine.
- Review current medicines for nephrotoxic interactions.
Q&A — “What If I Miss A Dose?”
Take the missed dose as soon as you remember unless it is close to the next scheduled dose.
Do not double up doses to make up for missed tablets.
If several doses are missed, contact your prescriber or pharmacist for tailored advice.
Interaction Chart
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
No major food interactions are reported with mesalazine formulations.
Alcohol may irritate the gut and worsen colitis symptoms, so advise moderation during flares.
Caffeine, spicy or acidic foods commonly present in Australian diets can increase gastrointestinal discomfort during an active flare.
Common Drug Conflicts
Mesalazine has relatively few systemic interactions but co‑use with nephrotoxic medicines raises renal risk.
Drugs that warrant caution include NSAIDs, ACE inhibitors, aminoglycosides and diuretics due to additive renal effects.
Caution with anticoagulants or antiplatelet agents if there is a history of sulfasalazine allergy or bleeding risk; monitor clinically.
| Interacting Drug | Mechanism | Recommended Action |
|---|---|---|
| NSAIDs (eg, ibuprofen) | Increased renal stress and possible additive nephrotoxicity | Avoid long‑term use; monitor renal function closely |
| ACE Inhibitors / ARBs | Potential additive renal impairment | Check baseline renal function; increase monitoring frequency |
| Diuretics | Can reduce renal perfusion | Monitor creatinine and electrolytes |
| Aminoglycosides | Nephrotoxicity risk | Avoid concurrent use where possible; monitor renal tests |
- Immediate flag in pharmacy software: nephrotoxic co‑medication, known sulfa/salicylate allergy, pregnancy/breastfeeding.
User Reports & Trends
Feedback From Australian Patients (ProductReview, Health Forums)
Patients commonly report good symptom control with mesalazine for induction and maintenance of ulcerative colitis.
Common tolerability issues mentioned include headache, nausea and abdominal discomfort.
Patients frequently raise concerns about renal monitoring and long‑term safety.
Price sensitivity and PBS access strongly influence brand selection and adherence.
Many patients value pharmacist counselling and consistent supply from a single pharmacy.
- Top 5 Reported Positives:
- Reduced bloody diarrhoea during induction.
- Improved quality of life when in remission.
- Convenient oral dosing compared with parenteral treatments.
- Well tolerated by many patients on maintenance doses.
- Rectal formulations effective for distal disease.
- Top 5 Reported Issues:
- Worry about kidney tests and frequency.
- Headaches and mild nausea for some users.
- Supply and cost concerns when PBS access is limited.
- Confusion over different brand release mechanisms.
- Concerns about use in pregnancy and breastfeeding.
Anonymous patient comment: “Asacol helped my flare within weeks but my GP wanted bloods checked regularly which I appreciate.”
Anonymous comment: “The tablets upset my stomach at first but settling the dose and timing helped.”
| Sentiment | Common Themes | Rural Vs Metropolitan |
|---|---|---|
| Positive | Efficacy for ulcerative colitis, maintenance benefit | Both regions report benefit; metropolitan patients report faster access to specialists |
| Negative | Monitoring burden, cost, transient side effects | Rural patients report longer waits and delivery concerns |
Access & Purchase Options
National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)
Major pharmacy chains dispense prescribed mesalazine products subject to stock and sponsor supply.
Pack sizes commonly available are 30, 60 and 90 tablets and out‑of‑pocket cost depends on PBS subsidy and brand.
Chains may offer price comparisons, but PBS status determines the insured cost for eligible patients.
Online Pharmacies And Telehealth E‑Prescriptions
Telehealth e‑prescriptions and online pharmacy dispensing can be used to obtain mesalazine in Australia from registered pharmacies.
Reputable online pharmacies must hold Australian pharmacy registration and supply only on a valid prescription.
Rural patients often use mail order for supply; mesalazine does not require cold chain and should be stored at 15–30°C during transit.
In our online pharmacy, mezavant is available without a prescription, with discreet delivery to Australia in 9‑21 days.
| Purchase Channel | Pros | Cons | Expected Delivery Time |
|---|---|---|---|
| Community Pharmacy | Immediate advice and face‑to‑face counselling | May have limited stock of specific brands | Same day to 48 hours |
| National Chain | Price comparisons, reliable stock | Can be busier; wait times for pharmacist consultation | 1–3 days |
| Online Registered Pharmacy | Convenient for repeat scripts and rural delivery | Requires valid e‑prescription and verification process | 3–21 days depending on location |
Checklist — What To Verify Before Ordering Online
- Pharmacy registration and Australian pharmacy details on the website.
- Requirement for a valid prescription and how to submit it.
- Pack size, brand and exact strength match prescriber instructions.
- Delivery times, returns policy and privacy assurances for health information.
Mechanism & Pharmacology
Simplified Explanation
Mesalazine is a topical anti‑inflammatory that works on the colonic mucosa to reduce local inflammation.
Delayed‑release and extended‑release formulations are designed to release active drug in the colon and limit systemic absorption.
Targeted release reduces the likelihood of systemic adverse effects while delivering therapeutic concentrations to the bowel lining.
ATC classification is A07EC02 — intestinal anti‑inflammatory agents, aminosalicylic acid class.
Clinical Terms
- Induction: the initial treatment phase to control an acute flare and bring the disease into remission.
- Maintenance: ongoing treatment to prevent relapse after remission is achieved.
- Entero‑coating / Delayed‑release: formulation designed to withstand stomach acid and release the drug in the intestines or colon.
- Systemic absorption: the amount of drug entering the bloodstream; mesalazine aims for low systemic absorption.
| Brand | Release Mechanism | Typical Dose |
|---|---|---|
| Asacol | Delayed‑release, colonic targeting | 400 mg or 800 mg formulations; 2.4–4.8 g/day induction |
| Pentasa | Sustained‑release | Formulation dependent; follow product directions |
Indications & Off‑Label Uses
Approved Indications By TGA
Mesalazine is used for induction and maintenance of remission in ulcerative colitis and for distal disease such as proctitis or proctosigmoiditis where product approvals apply.
Prescribers and pharmacists should check the ARTG entry for the exact product to confirm approved indications locally.
Off‑Label Uses In Australian Clinical Practice
Occasional off‑label uses include treatment of pouchitis or selected mild ileal disease depending on clinician judgement and patient factors.
Off‑label use should be documented with informed consent and a clear rationale in the patient record.
- Approved: Induction and maintenance of ulcerative colitis, proctitis/proctosigmoiditis where the product ARTG indicates.
- Off‑Label: Pouchitis or limited Crohn’s involvement in some cases; evidence is limited and specialist input is often sought.
Key Clinical Findings
Major Australian And International Studies 2022–2026
High‑quality evidence continues to support mesalazine for inducing and maintaining remission in mild‑to‑moderate ulcerative colitis.
Extended‑release and delayed‑release mesalazine formulations achieve colon‑targeted delivery with lower systemic exposure.
Mesalazine shows limited benefit in Crohn’s disease compared with its effects in ulcerative colitis.
Renal adverse events are rare but important; routine renal monitoring is effective at identifying early dysfunction.
| Study | Population | Outcome | Relevance |
|---|---|---|---|
| Randomised Trials (Various) | Mild–moderate UC patients | Improved remission rates with standard mesalazine dosing | Supports induction and maintenance regimens in Australian practice |
| Formulation Comparisons | Adults with distal disease | Targeted release reduced systemic exposure | Guides brand selection where colonic targeting is required |
- Clinical Takeaways: monitor renal function, use appropriate release formulation for disease location, document rationale for off‑label use.
- Pharmacists: reinforce monitoring schedule and adherence to induction and maintenance dosing.
Alternatives Matrix
PBS‑Listed Alternatives Comparison Table
| Drug | Formulation | Typical Dose | PBS Status | Key Pros / Cons |
|---|---|---|---|---|
| Asacol | Delayed‑release tablets (400 mg, 800 mg) | 2.4–4.8 g/day induction | Product dependent | Good colonic targeting; pack sizes common |
| Pentasa | Sustained‑release oral | Dose dependent on formulation | Product dependent | Steady release; may suit some patients |
| Mezavant | Extended‑release oral | Formulation specific dosing | Product dependent | Extended release for once‑daily dosing in some cases |
| Topical Mesalazine | Suppository / Enema | Use as prescribed | Product dependent | Useful for distal disease; direct mucosal delivery |
Pros And Cons Checklist
- Onset of action: oral vs topical formulations differ; topical acts locally and faster for distal disease.
- Rectal versus oral targeting: choose rectal for proctitis or proctosigmoiditis where appropriate.
- Adherence: once‑daily extended‑release formulations can improve adherence for some patients.
- Cost and PBS availability affect long‑term access and adherence.
- All options require renal monitoring and allergy screening.
Common Questions (Pharmacy FAQs)
Top FAQs Seen In Australian Consultations
- Is It Safe Long Term? Mesalazine is commonly used long term for maintenance with periodic review and renal monitoring.
- How Often Do I Need Renal Tests? Baseline creatinine before starting, repeat at 2–4 weeks, then approximately every three months for the first year and periodically after that.
- Can Children Take It? Certain 400 mg products (eg, Asacol 400 mg) are approved for children aged five and older; 800 mg products are generally adult formulations.
- What If Symptoms Worsen? Seek GP or gastroenterologist review urgently; worsening bloody diarrhoea or severe abdominal pain may indicate active disease or adverse reaction.
Pharmacist Counselling Script Example: “This medicine is for ulcerative colitis. Please have baseline blood tests before starting, and return for tests at 2–4 weeks, then as advised. Take it with water and avoid doubling doses. Report dizziness, rash or reduced urine output immediately.”
Price & Access Comparison Table
Comparison Table — Pharmacy Source, Typical Price Range, PBS Subsidy Status, Prescription Required
| Source | Brand | Pack Sizes | Typical Price Range (AUD) | PBS Status | Rx Required |
|---|---|---|---|---|---|
| Community Pharmacy | Asacol / Generics | 30 / 60 / 90 | Varies by brand and PBS; check current prices | Product dependent | Yes |
| National Chain | Asacol, Pentasa | 30 / 60 / 90 | Varies; price comparison available in stores | Product dependent | Yes |
| Online Pharmacy | Generics / Asacol | 30 / 60 / 90 | Varies; delivery fees may apply | Product dependent | Yes (or via e‑prescription) |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Check local stock and substitution options at the pharmacy.
- Confirm whether the product is PBS‑listed and whether authority scripts are required.
- Allow extra delivery time for rural and remote areas and verify shipping terms.
- Verify ARTG sponsor details for imported products if applicable.
- Consider pharmacist follow‑up for first supply and monitoring reminders.
Registration & Regulation
TGA Approval
Pharmacists and prescribers should check the Australian Register of Therapeutic Goods (ARTG) for specific mesalazine product registrations and approved indications.
Not all international brands are automatically available in Australia; ARTG entries confirm authorised supply.
PBS Subsidy Details
PBS listing varies by formulation and indication and often requires prescriber compliance with authority rules for subsidised supply.
Pharmacists must confirm patient entitlement, concession status and whether an authority number is required at dispensing.
- Definitions:
- ARTG: Australian Register of Therapeutic Goods — product registration list.
- PBS: Pharmaceutical Benefits Scheme — subsidy program for listed medicines.
- Authority Script: Prescriber request for PBS subsidy when special criteria must be met.
Storage & Handling
Household Storage In Australian Climate (Heat/Humidity)
Store mesalazine between 15–30°C and protect from moisture and direct sunlight.
Avoid storing tablets in bathrooms or near heat sources where humidity and temperature spikes can occur.
In very hot Australian summers, suggest keeping the medicine in a cool, dry cupboard away from direct sun to protect stability.
Cold‑Chain Handling For Pharmacies
No cold chain is required for mesalazine products.
Pharmacies should store at ambient recommended temperatures, keep blister packs intact and maintain storage logs as part of standard Good Pharmacy Practice.
Patient Counselling Checklist On Storage
- Keep in the original container with child‑resistant closure where provided.
- Do not refrigerate or freeze; keep below 30°C.
- If tablets have been exposed to extreme heat, advise pharmacist review and possible replacement.
| Do | Don’t |
|---|---|
| Keep in original pack | Store in bathroom or near the oven |
| Check expiry dates | Use if tablets are discoloured or damaged |
Guidelines For Proper Use
Australian Pharmacist Counselling Style
Start counselling by confirming the indication and reviewing allergy history for salicylates or sulfasalazine.
Explain the dosing schedule, how to take delayed‑release tablets and what to do if a dose is missed.
Emphasise the need for baseline blood tests and a clear renal monitoring plan.
Review common side effects and urgent red flags such as severe abdominal pain, chest pain, shortness of breath or new blood in stool that require immediate medical review.
Patient Advice From PBS And National Health Authorities
Encourage patients to keep repeat prescriptions current and to claim PBS subsidies where eligible.
Offer printed leaflets, translated resources or links to culturally appropriate support for Indigenous and culturally and linguistically diverse patients.
Record counselling and arrange follow‑up contact or pharmacist review to support adherence and monitoring.
- Patient Handout Template: indication, dose, monitoring timeline, common side effects, emergency contacts and when to see GP/gastroenterologist.
- Urgent Red Flags Quick Reference: severe abdominal pain, high fever, chest pain, sudden breathlessness, reduced urine output.
- Monitoring Timeline Quick Reference: baseline bloods, 2–4 week check, 3‑monthly in first year, then periodic checks.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9–14 days |
| Melbourne | Victoria | 9–14 days |
| Brisbane | Queensland | 9–14 days |
| Perth | Western Australia | 9–14 days |
| Adelaide | South Australia | 9–14 days |
| Canberra | Australian Capital Territory | 9–14 days |
| Hobart | Tasmania | 9–14 days |
| Darwin | Northern Territory | 9–14 days |
| Gold Coast | Queensland | 9–14 days |
| Newcastle | New South Wales | 9–14 days |
| Wollongong | New South Wales | 9–14 days |
| Geelong | Victoria | 9–14 days |
| Townsville | Queensland | 14–21 days |
| Cairns | Queensland | 14–21 days |
| Sunshine Coast | Queensland | 14–21 days |
Closing Notes
Mesalazine (mezavant) remains a mainstay for induction and maintenance of remission in ulcerative colitis where appropriate.
Pharmacists play a central role in screening for allergy and renal risk, counselling on proper use and ensuring monitoring is in place.
Always consult the specific product leaflet and the ARTG entry for brand‑specific dosing and contraindications.
If a patient is unsure about monitoring or experiences worrying symptoms, advise immediate review with the GP or gastroenterologist.